VG-3927 - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Eli Lilly’s retatrutide moves closer to a planned 2027 U.S. filing after completing its core Phase 3 programme for obesity, knee pain and sleep apnea. Representative image.

Retatrutide development: Phase 3 results, 2027 FDA filing, TRIUMPH trials and what comes next

India and Canada are accelerating CEPA negotiations as LNG, nuclear energy and critical minerals become central to their expanding economic relationship. Representative image.

Canada targets India trade deal by year-end as LNG, nuclear and critical minerals talks deepen

The White House press-access dispute intensified after MS NOW journalists said their credentials were disabled following Donald Trump’s media ban. Representative image.

Trump White House media ban takes effect as MS NOW journalists are turned away

Smoke near Riyadh’s King Khalid International Airport followed Saudi aerial danger alerts as the conflict with Yemen’s Houthis intensifies. Representative image.

Smoke rises near Riyadh airport after Saudi aerial alerts as Houthi conflict escalates

Sanofi Moves to Acquire Vigil Neuroscience for $470 Million, Targeting TREM2-Based Alzheimer’s Therapy VG-3927

Read More

Pharma Industry News

Sanofi to acquire Vigil Neuroscience for $470m to advance TREM2-targeting Alzheimer’s therapy

Sanofi to acquire Vigil Neuroscience for $470M, aiming to add VG-3927, a TREM2-based Alzheimer’s drug, to its neurology pipeline.

byPallavi Madhiraju

May 23, 2025

web analytics